Independent Financial Group LLC Acquires Shares of 2,605 Illumina, Inc. $ILMN

Independent Financial Group LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,605 shares of the life sciences company’s stock, valued at approximately $321,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. HighPoint Advisor Group LLC lifted its position in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Illumina by 0.3% during the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares during the period. Panagora Asset Management Inc. grew its position in Illumina by 3.9% in the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after buying an additional 96 shares during the last quarter. Venturi Wealth Management LLC increased its stake in Illumina by 4.2% in the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock valued at $323,000 after buying an additional 99 shares during the period. Finally, Banque Cantonale Vaudoise raised its position in Illumina by 1.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 7,071 shares of the life sciences company’s stock worth $927,000 after buying an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In other Illumina news, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the sale, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the sale, the director owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ILMN. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Canaccord Genuity Group boosted their target price on Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Piper Sandler raised their price target on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 1st. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Finally, Royal Bank Of Canada initiated coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average price target of $156.88.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Neutral Sentiment: Illumina was highlighted in a batch of valuation and relative-performance articles comparing it with peers such as Exelixis and Celldex Therapeutics, which may be keeping attention on whether ILMN looks cheap or expensive versus other healthcare names. EXEL vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Analyst sentiment remained middling, with Illumina reported as having an average “Hold” recommendation, suggesting Wall Street is not seeing an immediate reason to aggressively buy or sell the shares. Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: Coverage around Illumina’s role in the Billion Cell Atlas alliance and broader genomics/CRISPR collaboration was noted in commentary on AstraZeneca, but this appears more like a long-term strategic backdrop than a near-term stock mover. AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
• Neutral Sentiment: Short-interest data showed no meaningful change in reported shares outstanding for short positions, so there is no clear evidence here of a new bearish squeeze or panic selling signal.

Illumina Trading Down 1.4%

NASDAQ:ILMN opened at $194.09 on Friday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $199.14. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The stock has a fifty day simple moving average of $171.24 and a 200-day simple moving average of $145.40. The company has a market capitalization of $29.37 billion, a PE ratio of 35.29, a price-to-earnings-growth ratio of 2.87 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities research analysts expect that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.